487 related articles for article (PubMed ID: 11362832)
1. Update on HIV protease inhibitors.
Vella S
AIDS Clin Care; 1995 Oct; 7(10):79-82, 88. PubMed ID: 11362832
[TBL] [Abstract][Full Text] [Related]
2. Conference looks at HIV drug resistance.
Chang HE
GMHC Treat Issues; 1995 Sep; 9(9):6-8. PubMed ID: 11362910
[TBL] [Abstract][Full Text] [Related]
3. Protease inhibitors and prevention of cross resistance.
Levin J
AIDS Treat News; 1995 Oct; (no 232):1-3. PubMed ID: 11362875
[TBL] [Abstract][Full Text] [Related]
4. Protease inhibitors shine in triple combinations.
AIDS Alert; 1996 Mar; 11(3):31-2. PubMed ID: 11363243
[TBL] [Abstract][Full Text] [Related]
5. Nipping HIV in the bud.
Smart T
GMHC Treat Issues; 1996 Aug; 10(8):3-6. PubMed ID: 11363719
[TBL] [Abstract][Full Text] [Related]
6. New drugs for HIV infection.
Med Lett Drugs Ther; 1996 Apr; 38(972):35-7. PubMed ID: 8606677
[TBL] [Abstract][Full Text] [Related]
7. Ritonavir: first to prolong survival.
MacDougall DS
J Int Assoc Physicians AIDS Care; 1996 Apr; 2(4):38-44. PubMed ID: 11363517
[TBL] [Abstract][Full Text] [Related]
8. No tease this time--pros and cons of a long-awaited anti-HIV drug.
Chang HE
Posit Aware; 1996; 7(1):18-20. PubMed ID: 11363118
[TBL] [Abstract][Full Text] [Related]
9. Merck protease inhibitor: more news from Retroviruses Conference.
James JS
AIDS Treat News; 1996 Feb; (no 241):1-3. PubMed ID: 11363186
[TBL] [Abstract][Full Text] [Related]
10. [Which is the strategy? The latest in the use of antiretrovirals].
Agosto M
Sidahora; 1995; ():33-4. PubMed ID: 11363205
[TBL] [Abstract][Full Text] [Related]
11. Protease inhibitor trials moving to next phase.
AIDS Alert; 1995 Aug; 10(8):100-1. PubMed ID: 11362675
[TBL] [Abstract][Full Text] [Related]
12. Potent new AIDS drugs underscore promise of combination therapy.
AIDS Alert; 1996 Jan; 11(1):1-4. PubMed ID: 11363225
[TBL] [Abstract][Full Text] [Related]
13. Protease inhibitors-at-a-glance.
Notes Undergr; 1996 Apr; (no 32):4-5. PubMed ID: 11363449
[TBL] [Abstract][Full Text] [Related]
14. The choice of HIV protease inhibitor: indinavir is currently the best option.
Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
[TBL] [Abstract][Full Text] [Related]
15. Freedom of choice.
Vazquez E
Posit Aware; 1996; 7(3):9, 19. PubMed ID: 11363432
[TBL] [Abstract][Full Text] [Related]
16. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
Collier AC; Coombs RW; Schoenfeld DA; Bassett RL; Timpone J; Baruch A; Jones M; Facey K; Whitacre C; McAuliffe VJ; Friedman HM; Merigan TC; Reichman RC; Hooper C; Corey L
N Engl J Med; 1996 Apr; 334(16):1011-7. PubMed ID: 8598838
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
18. Saquinavir: combination shows survival benefit; new formulation trial recruiting.
AIDS Treat News; 1996 May; (no 246):1-2. PubMed ID: 11363484
[TBL] [Abstract][Full Text] [Related]
19. FDA triple header. Food and Drug Administration.
Smart T
GMHC Treat Issues; 1995 Nov; 9(11):1-3. PubMed ID: 11362986
[TBL] [Abstract][Full Text] [Related]
20. FDA approves 2 new protease inhibitors: ritonavir (Norvir) and Crixivan (Indinavir sulfate). Food and Drug Administration.
Schouten JT
STEP Perspect; 1996; 8(1):7-8. PubMed ID: 11363592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
